ProductsPricingResearchSupportPartner

₹ 14112 / 14 shares

IPO Details

RHP/DRHP

Issue Date

03 Jul - 5 Jul'24

Investment/lot

₹ 14112

Price Range

960 - 1008

Lot Size

14

IPO Size

₹ 1953.01 Cr

IPO Listing Details

Listing On

10 Jul'24

Issue Price

1008

Listed Price

₹ 1325.05

Retail Gain/Listing Gain

31.45%

Start date

End date

Allotment of bids

Refund Initiation

Listing on exchange

WATCH AND LEARN
All you need to know about Emcure Pharma Limited IPO
Tune in to know more about the company, IPO issue details, product/service portfolio, and much more with Kinjal Parekh!

Emcure Pharmaceuticals is an Indian pharmaceutical company that develops, manufactures and globally markets a broad range of pharmaceutical products across several major therapeutic areas.

It is a research and development (R&D) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which enables them to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada.

With that, let's take a look at the competitive strengths and risk factors for Emcure Pharmaceuticals Limited:

Well-placed to leverage their position in the domestic market

The company is focused on the domestic market, with sales in India contributing 48.28% of their total revenue for FY24. Since shifting their focus to Indian domestic branded generics in 1995, they have grown significantly. They are now the 13th largest pharmaceutical company in India by Domestic Sales for MAT FY24, the 4th largest by market share in their covered markets, and the largest in the gynecology and HIV antivirals therapeutic areas in India (Source: CRISIL Report).

Demonstrated capabilities of building brands

They have demonstrated strong capabilities and a proven track record in building brands. Six of their brands were ranked among the 300 highest-selling brands in the IPM in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report). Additionally, 16 of their top 20 brands were each ranked among the three highest-selling brands in their respective therapeutic areas in the IPM for the same period (Source: CRISIL Report).

Large, diversified and fast-growing product portfolio in international markets

They sell their portfolio of products in over 70 countries, with Europe and Canada being their primary international markets. Sales outside India contributed 51.72% of their total revenue for the FY24.
  • Any manufacturing or quality control problems may damage the company’s reputation and subject them to regulatory action, which could adversely affect the business.

  • Failure to comply with applicable quality standards may result in product liability claims, which could adversely affect the business, financial condition, cash flows and results of operations.

  • Any disruptions to the supply, or an increase in the pricing of raw materials and finished products that are outsourced, may adversely affect the business, cash flows, financial condition and results of operations.

Key Strategies

  • Increase market share in the domestic market.

  • Continue to invest in R&D and manufacturing capabilities to enhance and grow their differentiated product portfolio.

  • Pursue strategic acquisitions, partnerships and in-licensing arrangements.

Here are the key financials for Emcure Pharmaceuticals Limited:

Particulars (in Rs. million)

Particulars (in Rs. million)

WHAT ARE YOU LOOKING FOR?
Applying for an IPO for the first time?
Here's a video playlist to help you invest in the upcoming Indegene Limited IPO
How to apply for IPO through ASBA

How to apply for IPO through ASBA

Kotak Securities

04m 01s

Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO.

Here are the steps to apply for Emcure Pharmaceuticals Ltd IPO:

Step 1: Log in to your Kotak Securities Demat account Log in to your Demat account to access IPO investments. Next, select the current IPO section.

Step 2: Specify IPO details Enter the number of lots and the price you wish to apply for.

Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.

Step 4: Mandate Notification Your UPI app will receive a mandate notification to block funds.

Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.

Emcure Pharma IPO FAQs

Emcure Pharma IPO will list on 2024-07-10.

1953.01 is the issue size of Emcure Pharma IPO.

The minimum lot size is 14 shares and the investment required is ₹14112.

The price band of Emcure Pharma IPO is ₹960 to ₹1008.

You can read more about Emcure Pharma and its IPO from the company’s red herring prospectus (RHP) here.

The Emcure Pharmaceuticals Limited IPO has an issue size of Rs. 1,952 crores. The IPO opens for subscription on 3rd July 2024 and closes on 5th July 2024

Link Intime India Private Limited is the registrar for this IPO.

Open Demat Account to Invest in any IPO
+91 -

personImage
Open Demat Account to Invest in any IPO
+91 -